Merck to acquire Peloton in $1.05B cash-deal

Note: This section contains information in English only.
Source: Dukascopy Bank SA
On Tuesday, Merck & Co stated it would acquire the cancer drug developer Peloton Therapeutics in a cash deal valued at $1.05B, seeking to receive access to the firm's renal cancer medication candidate PT2977.

Actual Topics

Subscribe to "Fundamental Analysis" feed

Souscrire
To learn more about Dukascopy Bank CFD / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
For further information regarding potential cooperation,
please call us or make callback request.
To learn more about Dukascopy Bank Binary Options / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
To learn more about Dukascopy Bank CFD / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
To learn more about Crypto Trading / CFD / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
To learn more about Business Introducer and other trading related information,
please call us or make callback request.
For further information regarding potential cooperation,
please call us or make callback request.